<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699539</url>
  </required_header>
  <id_info>
    <org_study_id>Changhai Hospita</org_study_id>
    <nct_id>NCT04699539</nct_id>
  </id_info>
  <brief_title>Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>GTV Uniform Expansion to Form PTV vs. Non-uniform Expansion to Form PTV Based on Recurrence Pattern in SBRT of Locally Advanced Pancreatic Cancer: a Phase III Clinical Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of two target delineation&#xD;
      methods in SBRT for LAPC, so as to determine whether the target delineation method based on&#xD;
      recurrence pattern can obtain better survival benefits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year Local Control Rate (1y-LCR)</measure>
    <time_frame>1-year</time_frame>
    <description>Local Control Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Probability of gastrointestinal (GI) Toxicity</measure>
    <time_frame>1-year</time_frame>
    <description>gastrointestinal toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Disease Progression-Free-Survival (DPFS)</measure>
    <time_frame>1-year</time_frame>
    <description>Disease Progression-Free-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>1-year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">382</enrollment>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GTV uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GTV non-uniform expansion to form PTV in SBRT combined with Gemcitabine + albumin-bound paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT: in 5-6fractions with Cyberknife.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8), repeat every 3 weeks.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  Patients with a pathological diagnosis of pancreatic ductal adenocarcinoma or clinical&#xD;
             diagnosis of pancreatic cancer after clinical multiple disciplinary team&#xD;
&#xD;
          -  Patients with a clinical staging of locally advanced pancreatic cancer&#xD;
&#xD;
          -  No anti-tumor treatment related to pancreas before SBRT&#xD;
&#xD;
          -  Performance status is acceptable, ECOG score is 0 or 1&#xD;
&#xD;
          -  Patients who voluntarily accepted the clinical trial program after informing the&#xD;
             existing treatment plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously received relevant treatments in the pancreas and its&#xD;
             surrounding areas, such as radiotherapy, chemotherapy, and local treatment&#xD;
&#xD;
          -  Severe liver and kidney dysfunction&#xD;
&#xD;
          -  Obstructive jaundice&#xD;
&#xD;
          -  Moderate or mass ascites&#xD;
&#xD;
          -  Patients with other malignant tumors, acute infection or other severe infection&#xD;
&#xD;
          -  Patients with gastrointestinal ulcers and incomplete recovery, or patients with acute&#xD;
             peptic ulcer&#xD;
&#xD;
          -  Gastroscopy or imaging examination indicates that the tumor invaded the duodenum or&#xD;
             stomach&#xD;
&#xD;
          -  Patients who have participated in other clinical trials for less than three months&#xD;
&#xD;
          -  Patients who are judged by researchers as unsuitable for this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huojun Zhang, M.D.</last_name>
    <phone>021-31162207</phone>
    <email>chyyzhj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingong Jiang, M.D.</last_name>
    <phone>021-31162214</phone>
    <email>jlarry1988@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huojun Zhang, M.D.</last_name>
      <phone>+8613311732399</phone>
      <email>chyyzhj@163.com</email>
    </contact>
    <investigator>
      <last_name>Huojun Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Huo Jun</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>SBRT</keyword>
  <keyword>Locally Advanced Pancreatic Cancer</keyword>
  <keyword>Target Delineation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

